David R. Epstein has served as a member of the Board of Directors since March 2017, and chairman since 2019. Mr. Epstein also currently serves as an Executive Partner at Flagship Pioneering, a life sciences innovation enterprise, and as a director at International Flavors & Fragrances, Inc. From January 2010 to July 2016, Mr. Epstein served as Chief Executive Officer of Novartis Pharmaceuticals, a Division of Novartis AG, a pharmaceutical company. Mr. Epstein received his M.B.A. from Columbia University Graduate School of Business.
Chief Executive Officer, and a member of the Board of Directors, since 2015. Simba has also served as a Venture Partner at Flagship Pioneering since 2015, and a member of the Board of Directors of Foghorn Therapeutics from 2017. From 2016 to 2019, Simba served as a Director at Realm Therapeutics PLC. From 2006 to 2015, Simba served as the President and Chief Executive Officer of moksha8 Pharmaceuticals, Inc and as a Partner at TPG Growth. Prior to these roles Simba was President and CFO at Maxygen from 1997 to 2006 and before that head of Corporate Development at Valentis and at Systemix. He worked at Boehringer Mannheim as co-head of Global Marketing for Recormon, Head of North Africa and Head of Corporate Development for the Elecsys Immunodiagnostic Platform. Simba is an immunologist and received his Ph.D. for early work on antibody drug discovery development from King’s College, London based on work done at Celltech. He received his M.B.A. from INSEAD. He has lived and worked in many countries and locations across the US, Latin America, Europe, the Middle East, Asia, and Africa.
Juan Andres has served as a member of the Board of Directors since December 2019. Mr. Andres has served as the Chief Technical Operations and Quality Officer at Moderna, Inc., a biotechnology company, since August 2017. He also has served on the Board of Directors at Avantor, Inc. since 2019. From January 2013 to June 2017, he was the Global Head of Technical Operations at Novartis AG, a pharmaceutical company. From August 2005 to January 2013, Mr. Andres held roles of increasing responsibility at Novartis, including Group Quality Head, Global Head of Technical Research and Development, and Global Pharmaceutical Operations Head. Mr. Andres holds a master’s degree in Pharmacy from Alcala de Henares University in Madrid, Spain and completed an advanced development program at London Business School.
Professor the Lord Ara Darzi of Denham has served as a member of the Board of Directors since February 2018. Lord Darzi also currently serves on the Board of Directors of HQI Holdings Limited, Health Quality Improvement LLC, Ara Darzi Qatar Limited, SQI Limited and SPI Investments Limited. He also currently serves as the Vice Chair of the Board of Governors of Sidra Medical and Research Center, Qatar, a Council Member at the Engineering and Physical Sciences Research Council, the Executive Chair of the World Innovation Summit for Health, as the Chair of Surgery at Imperial College London and as Professor of Surgery at the Institute of Cancer Research. From 2013 to 2015, Lord Darzi served as the Vice-Dean of Health Policy and Engagement at the Imperial College of London. Lord Darzi received his Medical Degree from Trinity College.
John Hohneker, M.D., has served a member of the Board of Directors since January 2021. Dr. Hohneker served as Chief Executive Officer of Anokion, a privately held biotechnology company, from January 2018 to January 2021. Prior to joining Anokion, Dr. Hohneker was the President of Research and Development at FORMA Therapeutics Inc., a biotechnology company. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, a pharmaceutical company, most recently as Senior Vice President and Global Head of Development for Immunology and Dermatology. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome, both pharmaceutical companies. Dr. Hohneker received his B.A. from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Robert Wood Johnson Medical School.
Julie H. McHugh has served as a member of the Board of Directors since April 2021. Ms. McHugh also has served on the Board of Directors of Aerie Pharmaceuticals since July 2015, Ironwood Pharmaceuticals, Inc. since February 2014, Lantheus Medical Imaging Inc. since February 2016, and Trevena, Inc. since July 2014. From May 2010 to May 2013, Ms. McHugh was Chief Operating Officer of Endo Health Solutions, Inc., a pharmaceutical company. From September 2008 to September 2009, she served as the Chief Executive Officer of Nora Therapeutics, Inc., a biopharmaceutical company. Before that, she was Company Group Chair for the worldwide virology business unit of Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods company, and served as President of Centocor, Inc., a subsidiary of Johnson & Johnson. Ms. McHugh received her M.B.A. from Saint Joseph’s University and her B.S. from Pennsylvania State University.